Groupe la Francaise’s ImmunityBio IBRX Stock Holding History

Groupe la Francaise’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,000	Closed	-$2.19K	–	600
2025 Q3	$2.19K	Buy	+1,000	New	+$2.58K	﹤0.01%	708

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Groupe la Francaise's IBRX Position: Q4 2025 in Review

Groupe la Francaise sold out of ImmunityBio (IBRX) in Q4 2025, closing a stake of 1,000 shares — an estimated $2.19K sold.

Groupe la Francaise first reported a position in IBRX in Q3 2025 and held it in 1 quarter. The position peaked at $2.19K in Q3 2025. 277 funds tracked by Wall St. Rank hold IBRX as of Q4 2025.

Groupe la Francaise reported no remaining ImmunityBio position as of Q4 2025 after selling out during the quarter.
Groupe la Francaise sold 1,000 ImmunityBio shares in Q4 2025, an estimated $2.19K.
Groupe la Francaise first reported a position in ImmunityBio in Q3 2025 and held it in 1 quarter.
Groupe la Francaise's ImmunityBio position peaked at $2.19K in Q3 2025.
277 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2025.

Based on Groupe la Francaise's 13F filing for Q4 2025, filed 12 Feb 2026.